Homepage
Full 18-step deep-dive · ~20–30 min · a member feature.
No report run on this ticker yet
Only preliminary foundational data below
Sign in to run a fresh report
Free · results in ~10 min
For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Monte Rosa Therapeutics, Inc. (GLUE) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Healthcare · Biotechnology
Boston, MA 02118, United States
monterosatx.com
Price
$16.52
Market Cap
$1.4B
Employees
187
Beta
1.56
Avg Volume
1,755,947
CEO
Dr. Markus Warmuth M.D.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing molecular glue degraders (MGDs), a class of small molecule drugs that harness the body's natural protein destruction mechanisms to selectively eliminate therapeutically relevant proteins. The company employs its proprietary Quantitative and Engineered Elimination of Neosubstrates (QuEEN) platform, which integrates artificial intelligence and experimental tools to enable target-centric discovery and rational design of MGD product candidates. Key pipeline assets include MRT-2359, an orally bioavailable MGD targeting the GSPT1 protein for potential treatment of MYC-driven tumors such as metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Additional candidates like MRT-6160 and MRT-8102 address needs in oncology and autoimmune diseases. Monte Rosa Therapeutics, Inc. operates within the biotechnology and medical research sector, advancing novel therapeutic modalities to tackle serious diseases through precision protein degradation.
Runs with full report
Earnings Schedule
Checked daily · calendar updated Aug 3 No upcoming print on the calendar yet — companies typically confirm a few weeks ahead. Last print was May 7, 2026.
EPS surprise history — vs analyst consensus · 5 prints of vendor history
+5.7%
Nov '25
-400.0%
Dec '25
-14.3%
Jan '26
-61.8%
Mar '26
-18.4%
May '26
| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| May 7, 2026 | $-0.38 | $-0.45 -18.4% | — | — |
| Mar 17, 2026 | $-0.34 | $-0.55 -61.8% | — | — |
| Jan 30, 2026 | $0.42 | $0.36 -14.3% | — | — |
| Dec 5, 2025 | $-0.02 | $-0.10 -400.0% | — | — |
| Nov 6, 2025 | $-0.35 | $-0.33 +5.7% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Jul 17, 2026 | 4 | View |
| Jul 16, 2026 | 4 | View |
| Jul 16, 2026 | 144 | View |
| Jul 15, 2026 | 144 | View |
| Jul 8, 2026 | SCHEDULE 13G/A | View |
| Jul 7, 2026 | 4 | View |
| Jul 6, 2026 | 4 | View |
| Jul 6, 2026 | SCHEDULE 13D/A | View |
| Jul 1, 2026 | 4 | View |
| Jun 30, 2026 | 144 | View |
| Jun 30, 2026 | 4 | View |
| Jun 30, 2026 | 4 | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Aug 3, 2026 2:40am (just now)
Current data · timestamped when a report runs
$16.52
Change · Aug 3
-6.16 (-27.16%)
Day Range
$14.87 – $16.85
52-Week Range
$4.12 – $25.77
50-Day MA
$20.78
200-Day MA
$18.16
Volume
7,467,200.00
Share Structure
Outstanding
84,321,705.00
Float
54,015,295.00
Free Float
64.1%
Normal free float
— 64.1% of shares trade freely, ~35.9% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
TD Twelve Data statement
HEX SEC filing
P/E Ratio (Price per dollar of earnings)
HEXStock Price / EPS (Diluted)
-35.53
Stock Price: $16.52
EPS (Diluted): -0.46
EPS (Diluted): -0.46
P/B Ratio (Price vs net asset value)
HEXStock Price / Book Value Per Share
5.89
Stock Price: $16.52
Total Equity: $233.06M
Shares: 83,071,185
Total Equity: $233.06M
Shares: 83,071,185
EV/EBITDA (Total value vs operating profit)
HEXEnterprise Value / EBITDA
-27.60
Market Cap: $1.40B
Total Debt: $0.00
Cash: $129.88M
EBITDA: -$45.85M
Total Debt: $0.00
Cash: $129.88M
EBITDA: -$45.85M
Enterprise Value (Takeover price (cap + debt - cash))
HEXMarket Cap + Total Debt - Cash
$1.3B
Market Cap: $1.40B
Total Debt: $0.00
Cash: $129.88M
Total Debt: $0.00
Cash: $129.88M
P/S Ratio (Price per dollar of revenue)
HEXStock Price / Revenue Per Share
11.10
Stock Price: $16.52
Revenue: $123.67M
Shares: 83,071,185
Revenue: $123.67M
Shares: 83,071,185
EV/Sales (Total value vs revenue — works when P/E can't)
CALC10.23
Gross Margin (Revenue left after direct costs)
HEXGross Profit / Revenue
—
Gross Profit: N/A
Revenue: $123.67M
Revenue: $123.67M
Missing from API: Gross Profit
Operating Margin (Revenue left after all operations)
HEXOperating Income / Revenue
-43.8%
Operating Income: -$54.21M
Revenue: $123.67M
Revenue: $123.67M
Net Margin (Revenue left as actual profit)
HEXNet Income / Revenue
-31.2%
Net Income: -$38.63M
Revenue: $123.67M
Revenue: $123.67M
ROE (Profit from shareholder equity)
HEXNet Income / Total Equity
-16.6%
Net Income: -$38.63M
Total Equity: $233.06M
Total Equity: $233.06M
ROIC (Profit from all invested capital)
HEXNOPAT / Invested Capital
-51.1%
Operating Income: -$54.21M
Tax Rate: 2.8%
Equity: $233.06M
Total Debt: $0.00
Cash: $129.88M
Tax Rate: 2.8%
Equity: $233.06M
Total Debt: $0.00
Cash: $129.88M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
HEXCurrent Assets / Current Liabilities
6.12
Current Assets: $393.19M
Current Liabilities: $64.21M
Current Liabilities: $64.21M
Debt/Equity (Leverage — debt vs equity)
HEXTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $233.06M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $233.06M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
HEXRevenue / Shares Outstanding
$1.49
Revenue: $123.67M
Shares: 83,071,185
Shares: 83,071,185
Book Value/Share (Net assets per share)
HEX(Total Assets - Total Liabilities) / Shares
$2.81
Total Equity: $233.06M
Shares: 83,071,185
Shares: 83,071,185
FCF/Share (Real cash generated per share)
HEX(Operating Cash Flow + CapEx) / Shares
$-0.33
Operating CF: -$22.80M
CapEx: -$4.70M
Shares: 83,071,185
CapEx: -$4.70M
Shares: 83,071,185
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TDLast Annual Dividend / Stock Price
—
Last Dividend: $0.00
Stock Price: $16.52
Stock Price: $16.52
Payout Ratio (Earnings paid out as dividends)
HEXDividends Paid / Net Income
0.0%
Dividends Paid: $0.00
Net Income: -$38.63M
Net Income: -$38.63M
Income Statement (Annual)
Last updated: Aug 3, 2026 2:40am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $75.6M | $123.7M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $72.9M | $112.4M | $143.3M | $156.7M | $177.9M |
| Operating Income | -$72.9M | -$112.4M | -$143.3M | -$81.1M | -$54.2M |
| Net Income | -$74.0M | -$108.5M | -$135.4M | -$72.7M | -$38.6M |
| EBITDA | -$70.8M | -$108.6M | -$137.1M | -$73.0M | -$45.9M |
| EPS | $-2.96 | $-2.30 | $-2.63 | $-0.98 | $-0.46 |
| EPS (Diluted) | $-2.96 | $-2.30 | $-2.63 | $-0.98 | $-0.46 |
Balance Sheet (Annual)
Last updated: Aug 3, 2026 2:40am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $346.1M | $54.9M | $128.1M | $224.3M | $129.9M |
| Total Current Assets | $348.7M | $275.9M | $236.2M | $377.4M | $393.2M |
| Total Assets | $366.3M | $342.4M | $303.8M | $438.7M | $448.7M |
| Current Liabilities | $16.6M | $25.6M | $46.6M | $156.9M | $64.2M |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $18.8M | $71.0M | $124.5M | $215.8M | $215.6M |
| Total Equity | $347.5M | $271.4M | $179.3M | $222.9M | $233.1M |
| Retained Earnings | -$122.0M | -$230.5M | -$365.9M | -$438.6M | -$477.2M |
Cash Flow (Annual)
Last updated: Aug 3, 2026 2:40am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$59.4M | -$92.5M | -$43.8M | $42.0M | -$22.8M |
| Capital Expenditure | -$9.7M | -$12.9M | -$19.0M | -$4.0M | -$4.7M |
| Free Cash Flow | -$69.1M | -$105.4M | -$62.8M | $38.0M | -$27.5M |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | $308.5M | -$291.2M | $72.5M | $96.4M | -$94.3M |
Growth Trends (YoY %)
Last updated: Aug 3, 2026 2:40am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | +63.5% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -54.2% | -27.5% | +43.4% | +33.2% |
| Net Income Growth | -46.7% | -24.7% | +46.3% | +46.9% |
| EBITDA Growth | -53.6% | -26.2% | +46.8% | +37.2% |
Industry Benchmarks
Compares GLUE against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for GLUE — it's generated by the pipeline (
market-narrative step).
Claude Reading
No AI findings yet for GLUE — they're generated by the
pipeline (
ai-findings step) when a report is run on this ticker.
GPT Reading
No GPT reading yet for GLUE — it's generated by the
pipeline (
gpt-critique step) after the other Big-3 seats, when a
report is run on this ticker.
Grok Reading
No Grok reading yet for GLUE — it's generated by the
pipeline (
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.
Advanced Analysis Forensic deep-dive · three lenses
Character & Durability Scorecard
Ten long-horizon business-character traits the Quality / Value / Sentiment lenses don’t break out, scored 1–10.
No scorecard yet for GLUE — the ten traits are scored by the
pipeline (
ext-scorecard step) when a report is run on this ticker.
No community reviews yet for GLUE.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · twelvedata
v1.1.501 · 34413680 · 2026-07-31 16:46:48